CHAMPIONS ONCOLOGY, INC.

Form 8-K January 07, 2013					
UNITED STATES SECURITIES AND EXCHANGE COMMISSION					
WASHINGTON, D.C. 20549					
FORM 8-K					
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF					
THE SECURITIES EXCHANGE ACT OF 1934					
Date of report (Date of earliest event reported): January 7, 2013					
CHAMPIONS ONCOLOGY, INC.					
(Exact name of registrant as specified in its charter)					
Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)					

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

Edgar Filing: CHAMPIONS ONCOLOGY, INC. - Form 8-K

(Address of Principal Executive Offices)
Registrant's telephone number, including area code: (201) 808-8400
Not Applicable
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

INFORMATION TO BE INCLUDED IN THE REPORT

On January 7, 2013, the Company prepared a presentation regarding its business.

A copy of the presentation is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

Other Events.

(d) Exhibits

Item 8.01.

The following exhibit is filed herewith:

Exhibit No.

99.1 Presentation.

Edgar Filing: CHAMPIONS ONCOLOGY, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHAMPIONS
ONCOLOGY, INC.
(Registrant)

Date: January 7, 2013 By: /s/ Joel Ackerman

Joel Ackerman

Chief Executive Officer